secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001420720-25-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio Q1 FY2026 revenue $0.1M; cash $49.6M; IBIO-610 half-life up to 100 days
----------------------------------------------------------------------------

- Revenue $0.1M vs $0 prior year; R&D expenses $3.6M (up $2.3M YoY); G&A $2.5M (down $0.3M).
- Cash $49.6M as of Sept 30, 2025, expected to fund operations into Q4 FY2027.
- Closed $50M public offering; potential additional $50M from common warrant exercise for total up to $100M.
- IBIO-610 NHP data shows predicted human half-life up to 100 days, enabling potential twice-yearly dosing.
- Regained Nasdaq compliance on Nov 4, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000039/0001420720-25-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000039/ibio-20251112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-25-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer